The MOLL trial - Magnetic lesion localisation for breast cancer
ISRCTN | ISRCTN74635349 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN74635349 |
Secondary identifying numbers | 35018 |
- Submission date
- 31/08/2017
- Registration date
- 20/09/2017
- Last edited
- 16/01/2018
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Contact information
Miss Mirjam Peek
Public
Public
Guy's Hospital
Research Oncology
Third floor Bermondsey Wing
Great Maze Pond
London
SE1 9RT
United Kingdom
0000-0001-5063-3998 | |
Phone | +44 2071880721 |
mirjam.peek@gstt.nhs.uk |
Study information
Study design | Non-randomised; Interventional; Design type: Treatment, Device, Imaging, Surgery |
---|---|
Primary study design | Interventional |
Secondary study design | Non randomised study |
Study setting(s) | Hospital |
Study type | Treatment |
Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
Scientific title | Magnetic Occult Lesion Localization for the surgical management of non-palpable Breast Cancer: The MOLL trial |
Study acronym | MOLL trial |
Study objectives | The aim of this study is to determine the feasibility of using the Tokyo magnetometer and a magnetic marker for wide localized excision in breast cancer. |
Ethics approval(s) | North East - York Research Ethics Committee, 04/07/2017, ref: 17/NE/0195 |
Health condition(s) or problem(s) studied | Specialty: Cancer, Primary sub-specialty: Breast Cancer; UKCRC code/ Disease: Cancer/ Malignant neoplasm of breast |
Intervention | There is no randomisation or separate treatment arms, as all participants included in the study follow the same procedure. On the morning prior to surgery the participant receives an injection with a magnetic marker which is placed into the centre of the non-palpable breast tumour. This is done instead of the standard procedure of inserting a wire used to localise breast tumours as it is no longer required. This procedure takes approximately 15 minutes (identification of the tumour, insertion of the marker and identification of the marker into the tumour). Participants undergo the wide local excision (WLE) surgery. The surgeon uses a hand-held magnetometer to detect the shortened wire (magnetic marker) and excise the whole tumour. This takes approximately 5 minutes (includes multiple detections during surgery). The surgery is undertaken as usual and the standard x-ray of the excised tissue is also be performed as standard. Participants are followed-up for one year, which is standard protocol. Participants are assessed to see if the magnetic marker and excision of the breast tumour is successful during surgery. Re-excision rates, cosmetic outcomes and morbidity are assessed post operatively. |
Intervention type | Other |
Primary outcome measure | Successful localization of a magnetic marker and excision of the breast tumour is assessed using a magnetic marker and magnetometer during surgery. |
Secondary outcome measures | 1. Re-excision rate is assessed by reviewing patient notes post-operatively 2. Excised specimen volumes are assessed by weighting the excised tissue volumes during surgery 3. Cosmetic outcome is assessed by reviewing patient notes post-operatively after 3 months and at 1 year follow-up 4. Morbidity from WLE is assessed by reviewing patient notes post-operatively |
Overall study start date | 01/04/2016 |
Completion date | 01/04/2019 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Lower age limit | 18 Years |
Sex | Both |
Target number of participants | Planned Sample Size: 20; UK Sample Size: 20 |
Key inclusion criteria | 1. Males/females (18 years or over) 2. A non-palpable breast tumour 3. Visible on ultrasound 4. Suitable for wire guided lesion localisation |
Key exclusion criteria | 1. Known intolerance / hypersensitivity to iron compounds 2. Patients with a pacemaker or other implantable devices in the chest wall |
Date of first enrolment | 21/09/2017 |
Date of final enrolment | 01/04/2018 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Guy's Hospital
Research Oncology
Third floor Bermondsey Wing
Great Maze Pond
London
SE1 9RT
United Kingdom
Third floor Bermondsey Wing
Great Maze Pond
London
SE1 9RT
United Kingdom
Sponsor information
Guy's and St Thomas' NHS Foundation Trust
Hospital/treatment centre
Hospital/treatment centre
Trust Offices
Guy's Hospital
Great Maze Pond
London
SE1 9RT
England
United Kingdom
https://ror.org/00j161312 |
Funders
Funder type
Government
Association of Breast Surgery
No information available
Results and Publications
Intention to publish date | 01/04/2019 |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not expected to be made available |
Publication and dissemination plan | Planned publication in a high-impact peer reviewed journal. Additional information such as the protocol is available on request. |
IPD sharing plan | The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication. |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
HRA research summary | 28/06/2023 | No | No |
Editorial Notes
16/01/2018: Cancer Help UK lay summary link added to plain English summary field
26/10/2017: Internal review.